SELLAS Life Sciences Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SELLAS Life Sciences Group (SLS) closed its underwritten public offering, raising $172.5 million in gross proceeds before fees and expenses.
SELLAS sold 13,269,231 common shares at $13.00 per share, including 1,730,769 additional shares purchased when the underwriters exercised their option in full. Gross proceeds are before underwriting discounts, commissions and offering expenses. Investors included new healthcare-focused institutions. J.P. Morgan and TD Cowen were the lead book-running managers.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointClosed public offering raised $172.5 million in gross proceeds 5.7% of market cap
- Minor pointNew healthcare-focused institutional investors participated in the offering
Negative
- Moderate point13,269,231 new common shares at $13.00 per share dilute existing holders, including 1,730,769 shares from the underwriters’ full option exercise
- Minor pointUnderwriting discounts, commissions and offering expenses reduce net proceeds
News Explained
At the third-quarter 2026 operating cash-use rate, the offering’s gross proceeds equal 2671.7 days of that outflow; this is a historical sizing comparison, not a forecast of cash runway.
Sources and calculations
- SELLAS offering-closing press release (2026-11-20)
- SELLAS third-quarter 2026 financial results (2026Q3)
- Offering gross against the last reported quarterly operating outflow, in days at that rate $172,500,000 / ($5,940,000 / 92) = 2671.7 days
Key Figures
- Shares offered
- 13,269,231 shares
- Common stock; completed underwritten public offering
- Offering price
- $13.00 per share
- Public offering price
- Underwriters’ option
- 1,730,769 additional shares
- Option exercised in full
- Gross proceeds
- $172.5 million
- Before underwriting discounts, commissions and offering expenses
Previous Offering Reports
-
Nov 17 proposed $150.0 million offering included a 30-day option; shares fell 6.27%.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
underwritten public offering financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Nov. 20, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the closing of its previously announced underwritten public offering of 13,269,231 shares of its common stock at a public offering price of
J.P. Morgan and TD Cowen acted as the lead book-running managers for the offering. Mizuho also acted as a book-running manager for the offering. A.G.P./Alliance Global Partners and Maxim Group LLC acted as lead managers for the offering.
The public offering was made pursuant to a shelf registration statement on Form S-3 (File No. 333-294504) that was previously filed with the Securities and Exchange Commission (the “SEC”) on March 20, 2026, and became automatically effective upon filing. The preliminary prospectus supplement and accompanying base prospectus and the final prospectus supplement relating to and describing the terms of the offering have been filed with the SEC and are available on the SEC’s website located at http://www.sec.gov. The offering was made only by means of a prospectus and related prospectus supplement, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmorganchase.com and postsalemanualrequests@broadridge.com; or TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com.
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib), a small molecule CDK9 inhibitor, for the treatment of AML in patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements related to the public offering. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties, including the risks and uncertainties inherent in SELLAS’ business, including those described in the company’s periodic filings with the SEC. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 19, 2026 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made.
Investor Contact
John Fraunces
Managing Director
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com
Media Contact
Joan Bosisio
VP, Scientific & Medical Communications
Simpson Healthcare
jbosisio@simpsonhealthcare.com
Source: SELLAS Life Sciences Group, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.